Role of inflammation in the pathogenesis of osteoarthritis: Latest findings and interpretations

Therapeutic Advances in Musculoskeletal Disease

Volumn 5, Issue 2, 2013, Pages 77-94

  Sokolove, Jeremy ^a   Lepus, Christin M ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

inflammation; innate Immunity; Osteoarthritis

Indexed keywords

ADIPONECTIN; AGGRECAN; ALPHA 1 MICROGLOBULIN; ALPHA 2 MACROGLOBULIN; BIGLYCAN; C REACTIVE PROTEIN; CALCIUM PHOSPHATE; CALCIUM PYROPHOSPHATE; CHEMERIN; COLLAGEN TYPE 2; COLLAGENASE 3; CRYOPYRIN; FIBRINOGEN; FIBRONECTIN; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; HYALURONIC ACID; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROSTAGLANDIN E2; PROTEIN S 100; RANTES; STROMELYSIN; TENASCIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; URATE; URIC ACID; VASCULOTROPIN; VITAMIN D BINDING PROTEIN;

AGE; ARTHRITIS; BIOMECHANICS; BONE MARROW EDEMA; CHONDROLYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; INNATE IMMUNITY; JOINT INJURY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; SYNOVIUM;

EID: 84885911247     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X12467868     Document Type: Article

References (131)

1. Altman R. Asch E. Bloch D. Bole G. Borenstein D. Brandt K. et al. (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29: 1039–1049.
2. Andriacchi T. Mundermann A. Smith R. Alexander E. Dyrby C. Koo S. (2004) A framework for the in vivo pathomechanics of osteoarthritis at the knee. Ann Biomed Eng 32: 447–457.
3. Aran S. Malekzadeh S. Seifirad S. (2011) A double-blind randomized controlled trial appraising the symptom-modifying effects of colchicine on osteoarthritis of the knee. Clin Exp Rheumatol 29: 513–518.
4. Attur M. Patel I. Patel R. Abramson S. Amin A. (1998) Autocrine production of IL-1 beta by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2, and IL-8. Proc Assoc Am Physicians 110: 65–72.
5. Ayral X. Pickering E. Woodworth T. Mackillop N. Dougados M. (2005) Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis – results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 13: 361–367.
6. Babelova A. Moreth K. Tsalastra-Greul W. Zeng-Brouwers J. Eickelberg O. Young M. et al. (2009) Biglycan, a danger signal that activates the NLRP 3 inflammasome via toll-like and P2X receptors. J Biol Chem 284: 24035–24048.
7. Benito M. Veale D. FitzGerald O. van den Berg W. Bresnihan B. (2005) Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 64: 1263–1267.
8. Blaney Davidson E. van der Kraan P. van den Berg W. (2007) TGF-beta and osteoarthritis. Osteoarthritis Cartilage 15: 597–604.
9. Bohnsack M. Meier F. Walter G. Hurschler C. Schmolke S. Wirth C. et al. (2005) Distribution of substance-P nerves inside the infrapatellar fat pad and the adjacent synovial tissue: a neurohistological approach to anterior knee pain syndrome. Arch Orthop Trauma Surg 125: 592–597.
10. Bondeson J. Blom A. Wainwright S. Hughes C. Caterson B. van den Berg W. (2010) The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum 62: 647–657.
11. Bondeson J. Wainwright S. Lauder S. Amos N. Hughes C. (2006) The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 8: R187.
12. Brandt K. Mazzuca S. Katz B. Lane K. Buckwalter K. Yocum D. et al. (2005) Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 52: 2015–2025.
13. Casale T. Abbas M. Carolan E. (1992) Degree of neutrophil chemotaxis is dependent upon the chemoattractant and barrier. Am J Respir Cell Mol Biol 7: 112–117.
14. Chauffier K. Laiguillon M. Bougault C. Gosset M. Priam S. Salvat C. et al. (2012) Induction of the chemokine IL-8/Kc by the articular cartilage: possible influence on osteoarthritis. Joint Bone Spine 15 February (Epub ahead of print).
15. Chen T. Chen L. Hsieh M. Chang C. Chou D. Tsai S. (2006) Evidence for a protective role for adiponectin in osteoarthritis. Biochim Biophys Acta 1762: 711–718.
16. Chen W. Bao J. Feng J. Hu P. Shi Z. Wu L. (2010) Increased serum concentrations of visfatin and its production by different joint tissues in patients with osteoarthritis. Clin Chem Lab Med 48: 1141–1145.
17. Chevalier X. Claudepierre P. Groult N. Zardi L. Hornebeck W. (1996) Presence of ED-A containing fibronectin in human articular cartilage from patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 23: 1022–1030.
18. Choe J. Bae J. Jung H. Park S. Lee H. Kim S. (2012) Serum resistin level is associated with radiographic changes in hand osteoarthritis: cross-sectional study. Joint Bone Spine 79: 160–165.
19. Clockaerts S. Bastiaansen-Jenniskens Y. Runhaar J. van Osch G. van Offel J. Verhaar J. et al. (2010) The infrapatellar fat pad should be considered as an active osteoarthritic joint tissue: a narrative review. Osteoarthritis Cartilage 18: 876–882.
20. Conaghan P. D'Agostino M. Le Bars M. Baron G. Schmidely N. Wakefield R. et al. (2010) Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis 69: 644–647.
21. Conde J. Scotece M. Gomez R. Lopez V. Gomez-Reino J. Gualillo O. (2011) Adipokines and osteoarthritis: novel molecules involved in the pathogenesis and progression of disease. Arthritis 2011: 203901.
22. Cunningham C. Mills E. Mielke L. O'Farrell L. Lavelle E. Mori A. et al. (2012) Osteoarthritis-associated basic calcium phosphate crystals induce pro-inflammatory cytokines and damage-associated molecules via activation of Syk and PI 3 kinase. Clin Immunol 144: 228–236.
23. Dahl I. Husby G. (1985) Hyaluronic acid production in vitro by synovial lining cells from normal and rheumatoid joints. Ann Rheum Dis 44: 647–657.
24. Dean G. Hoyland J. Denton J. Donn R. Freemont A. (1993) Mast cells in the synovium and synovial fluid in osteoarthritis. Br J Rheumatol 32: 671–675.
25. de Hooge A. van de Loo F. Bennink M. Arntz O. de Hooge P. van den Berg W. (2005) Male IL-6 gene knock out mice developed more advanced osteoarthritis upon aging. Osteoarthritis Cartilage 13: 66–73.
26. Denoble A. Huffman K. Stabler T. Kelly S. Hershfield M. McDaniel G. et al. (2011) Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci U S A 108: 2088–2093.
27. Dingle J. Saklatvala J. Hembry R. Tyler J. Fell H. Jubb R. (1979) A cartilage catabolic factor from synovium. Biochem J 184: 177–180.
28. Dumond H. Presle N. Terlain B. Mainard D. Loeuille D. Netter P. et al. (2003) Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 48: 3118–3129.
29. Englund M. Guermazi A. Gale D. Hunter D. Aliabadi P. Clancy M. et al. (2008) Incidental meniscal findings on knee MRI in middle-aged and elderly persons. N Engl J Med 359: 1108–1115.
30. Evans C. Mears D. McKnight J. (1981) A preliminary ferrographic survey of the wear particles in human synovial fluid. Arthritis Rheum 24: 912–918.
31. Farahat M. Yanni G. Poston R. Panayi G. (1993) Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 52: 870–875.
32. Felson D. (2006) Clinical practice. Osteoarthritis of the knee. N Engl J Med 354: 841–848.
33. Felson D. Anderson J. Naimark A. Walker A. Meenan R. (1988) Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med 109: 18–24.
34. Felson D. Kim Y. (2007) The futility of current approaches to chondroprotection. Arthritis Rheum 56: 1378–1383.
35. Felson D. McLaughlin S. Goggins J. LaValley M. Gale M. Totterman S. et al. (2003) Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med 139: 330–336.
36. Filkova M. Liskova M. Hulejova H. Haluzik M. Gatterova J. Pavelkova A. et al. (2009) Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis. Ann Rheum Dis 68: 295–296.
37. Foell D. Wittkowski H. Roth J. (2007) Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis. Nat Clin Pract Rheumatol 3: 382–390.
38. Gabay C. (2006) Interleukin-6 and chronic inflammation. Arthritis Res Ther 8(Suppl. 2): S3.
39. Geng Y. Blanco F. Cornelisson M. Lotz M. (1995) Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J Immunol 155: 796–801.
40. Giamarellos-Bourboulis E. Mouktaroudi M. Bodar E. van der Ven J. Kullberg B. Netea M. et al. (2009) Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process. Ann Rheum Dis 68: 273–278.
41. Gobezie R. Kho A. Krastins B. Sarracino D. Thornhill T. Chase M. et al. (2007) High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res Ther 9: R36.
42. Goldring M. Birkhead J. Sandell L. Kimura T. Krane S.M. (1988) Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes. J Clin Invest 82: 2026–2037.
43. Goldring M. Fukuo K. Birkhead J. Dudek E. Sandell L. (1994) Transcriptional suppression by interleukin-1 and interferon-gamma of type II collagen gene expression in human chondrocytes. J Cell Biochem 54: 85–99.
44. Gordon G. Villanueva T. Schumacher H. Gohel V. (1984) Autopsy study correlating degree of osteoarthritis, synovitis and evidence of articular calcification. J Rheumatol 11: 681–686.
45. Gosset M. Berenbaum F. Salvat C. Sautet A. Pigenet A. Tahiri K. et al. (2008) Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E 2 synthesis in chondrocytes: possible influence on osteoarthritis. Arthritis Rheum 58: 1399–1409.
46. Happonen K. Saxne T. Aspberg A. Morgelin M. Heinegard D. Blom A. (2010) Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum 62: 3574–3583.
47. Haraoui B. Pelletier J. Cloutier J. Faure M. Martel-Pelletier J. (1991) Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs. Arthritis Rheum 34: 153–163.
48. Hasturk H. Kantarci A. van Dyke T. (2012) Oral inflammatory diseases and systemic inflammation: role of the macrophage. Front Immunol 3: 118.
49. Haywood L. McWilliams D. Pearson C. Gill S. Ganesan A. Wilson D. et al. (2003) Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 48: 2173–2177.
50. He W. Pelletier J. Martel-Pelletier J. Laufer S. Di Battista J. (2002) Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. J Rheumatol 29: 546–553.
51. Hill C. Hunter D. Niu J. Clancy M. Guermazi A. Genant H. et al. (2007) Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis. Ann Rheum Dis 66: 1599–1603.
52. Homandberg G. Hui F. (1996) Association of proteoglycan degradation with catabolic cytokine and stromelysin release from cartilage cultured with fibronectin fragments. Arch Biochem Biophys 334: 325–331.
53. Homandberg G. Meyers R. Williams J. (1993) Intraarticular injection of fibronectin fragments causes severe depletion of cartilage proteoglycans in vivo. J Rheumatol 20: 1378–1382.
54. Homandberg G. Wen C. (1998) Exposure of cartilage to a fibronectin fragment amplifies catabolic processes while also enhancing anabolic processes to limit damage. J Orthop Res 16: 237–246.
55. Homandberg G. Wen C. Hui F. (1998) Cartilage damaging activities of fibronectin fragments derived from cartilage and synovial fluid. Osteoarthritis Cartilage 6: 231–244.
56. Honsawek S. Chayanupatkul M. (2010) Correlation of plasma and synovial fluid adiponectin with knee osteoarthritis severity. Arch Med Res 41: 593–598.
57. Hori O. Brett J. Slattery T. Cao R. Zhang J. Chen J. et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270: 25752–25761.
58. Hsu Y. Hsieh M. Liang Y. Li C. Sheu M. Chou D. et al. (2004) Production of the chemokine eotaxin-1 in osteoarthritis and its role in cartilage degradation. J Cell Biochem 93: 929–939.
59. Hui W. Litherland G. Elias M. Kitson G. Cawston T. Rowan A. et al. (2012) Leptin produced by joint white adipose tissue induces cartilage degradation via upregulation and activation of matrix metalloproteinases. Ann Rheum Dis 71: 455–462.
60. Hunter D. (2008) Are there promising biologic therapies for osteoarthritis? Curr Rheumatol Rep 10: 19–25.
61. Hunter D. Gerstenfeld L. Bishop G. Davis A. Mason Z. Einhorn T. et al. (2009) Bone marrow lesions from osteoarthritis knees are characterized by sclerotic bone that is less well mineralized. Arthritis Res Ther 11: R11.
62. Hunter D. Niu J. Zhang Y. LaValley M. McLennan C. Hudelmaier M. et al. (2008) Premorbid knee osteoarthritis is not characterised by diffuse thinness: the Framingham Osteoarthritis Study. Ann Rheum Dis 67: 1545–1549.
63. Huss R. Huddleston J. Goodman S. Butcher E. Zabel B. (2010) Synovial tissue-infiltrating natural killer cells in osteoarthritis and periprosthetic inflammation. Arthritis Rheum 62: 3799–3805.
64. Jiang D. Liang J. Fan J. Yu S. Chen S. Luo Y. et al. (2005) Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 11: 1173–1179.
65. Jones G. Sebba A. Gu J. Lowenstein M. Calvo A. Gomez-Reino J. et al. (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69: 88–96.
66. Kaneko S. Satoh T. Chiba J. Ju C. Inoue K. Kagawa J. (2000) Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther 6: 71–79.
67. Kawai T. Akira S. (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373–384.
68. Kim H. Cho M. Choi H. Yoon C. Jhun J. Oh H. et al. (2006) The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum 54: 2152–2163.
69. Knevel R. Schoels M. Huizinga T. Aletaha D. Burmester G. Combe B. et al. (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69: 987–994.
70. Krasnokutsky S. Belitskaya-Levy I. Bencardino J. Samuels J. Attur M. Regatte R. et al. (2011) Quantitative magnetic resonance imaging evidence of synovial proliferation is associated with radiographic severity of knee osteoarthritis. Arthritis Rheum 63: 2983–2991.
71. Ku J. Lee C. Joo B. An B. Choi S. Wang T. et al. (2009) Correlation of synovial fluid leptin concentrations with the severity of osteoarthritis. Clin Rheumatol 28: 1431–1435.
72. Kuroki K. Stoker A. Sims H. Cook J. (2010) Expression of toll-like receptors 2 and 4 in stifle joint synovial tissues of dogs with or without osteoarthritis. Am J Vet Res 71: 750–754.
73. Li Z. Cheng G. Hu K. Li M. Zang W. Dong Y. et al. (2011) Correlation of synovial fluid HMGB-1 levels with radiographic severity of knee osteoarthritis. Clin Invest Med 34: E298.
74. Libby P. (2002) Inflammation in atherosclerosis. Nature 420: 868–874.
75. Liu-Bryan R. Pritzker K. Firestein G. Terkeltaub R. (2005) TLR 2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol 174: 5016–5023.
76. Liu-Bryan R. Terkeltaub R. (2010) Chondrocyte innate immune myeloid differentiation factor 88-dependent signaling drives procatabolic effects of the endogenous toll-like receptor 2/toll-like receptor 4 ligands low molecular weight hyaluronan and high mobility group box chromosomal protein 1 in mice. Arthritis Rheum 62: 2004–2012.
77. Loeser R. (2006) Molecular mechanisms of cartilage destruction: mechanics, inflammatory mediators, and aging collide. Arthritis Rheum 54: 1357–1360.
78. Loeuille D. Sauliere N. Champigneulle J. Rat A. Blum A. Chary-Valckenaere I. (2011) Comparing non-enhanced and enhanced sequences in the assessment of effusion and synovitis in knee OA: associations with clinical, macroscopic and microscopic features. Osteoarthritis Cartilage 19: 1433–1439.
79. Lories R. Luyten F. (2011) The bone-cartilage unit in osteoarthritis. Nat Rev Rheumatol 7: 43–49.
80. Martel-Pelletier J. Pelletier J. Fahmi H. (2003) Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum 33: 155–167.
81. Martinon F. Petrilli V. Mayor A. Tardivel A. Tschopp J. (2006) Gout-associated uric acid crystals activate the NALP 3 inflammasome. Nature 440: 237–241.
82. McCarthy G. Cheung H. (1994) The role of cyclic-3′,5′-adenosine monophosphate in prostaglandin-mediated inhibition of basic calcium phosphate crystal-induced mitogenesis and collagenase induction in cultured human fibroblasts. Biochim Biophys Acta 1226: 97–104.
83. Melrose J. Fuller E. Roughley P. Smith M. Kerr B. Hughes C. et al. (2008) Fragmentation of decorin, biglycan, lumican and keratocan is elevated in degenerate human meniscus, knee and hip articular cartilages compared with age-matched macroscopically normal and control tissues. Arthritis Res Ther 10: R79.
84. Midwood K. Sacre S. Piccinini A. Inglis J. Trebaul A. Chan E. et al. (2009) Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 15: 774–780.
85. Morgan M. Whelan L. Sallis J. McCarthy C. Fitzgerald D. McCarthy G. (2004) Basic calcium phosphate crystal-induced prostaglandin E 2 production in human fibroblasts: role of cyclooxygenase 1, cyclooxygenase 2, and interleukin-1beta. Arthritis Rheum 50: 1642–1649.
86. Mow V. Lai W. Eisenfeld J. Redler I. (1974) Some surface characteristics of articular cartilage. II. On the stability of articular surface and a possible biomechanical factor in etiology of chondrodegeneration. J Biomech 7: 457–468.
87. Nair A. Kanda V. Bush-Joseph C. Verma N. Chubinskaya S. Mikecz K. et al. (2012) Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to TLR-4 and TLR-2 ligands via soluble CD14. Arthritis Rheum 64: 2268–2277.
88. Neogi T. Nevitt M. Niu J. LaValley M. Hunter D. Terkeltaub R. et al. (2006) Lack of association between chondrocalcinosis and increased risk of cartilage loss in knees with osteoarthritis: results of two prospective longitudinal magnetic resonance imaging studies. Arthritis Rheum 54: 1822–1828.
89. Nettelbladt E. Sundblad L. (1959) Protein patterns in synovial fluid and serum in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 2: 144–151.
90. Okamura Y. Watari M. Jerud E. Young D. Ishizaka S. Rose J. et al. (2001) The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276: 10229–10233.
91. Olee T. Hashimoto S. Quach J. Lotz M. (1999) IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J Immunol 162: 1096–1100.
92. Ospelt C. Neidhart M. Gay R. Gay S. (2004) Synovial activation in rheumatoid arthritis. Front Biosci 9: 2323–2334.
93. Park J. Svetkauskaite D. He Q. Kim J. Strassheim D. Ishizaka A. et al. (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279: 7370–7377.
94. Pauli C. Grogan S. Patil S. Otsuki S. Hasegawa A. Koziol J. et al. (2011) Macroscopic and histopathologic analysis of human knee menisci in aging and osteoarthritis. Osteoarthritis Cartilage 19: 1132–1141.
95. Pazar B. Ea H. Narayan S. Kolly L. Bagnoud N. Chobaz V. et al. (2011) Basic calcium phosphate crystals induce monocyte/macrophage IL-1beta secretion through the NLRP 3 inflammasome in vitro. J Immunol 186: 2495–2502.
96. Pearle A. Scanzello C. George S. Mandl L. DiCarlo E. Peterson M. et al. (2007) Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage 15: 516–523.
97. Pelletier J. Raynauld J. Abram F. Haraoui B. Choquette D. Martel-Pelletier J. (2008) A new non-invasive method to assess synovitis severity in relation to symptoms and cartilage volume loss in knee osteoarthritis patients using MRI. Osteoarthritis Cartilage 16(Suppl. 3): S8–S13.
98. Pfander D. Heinz N. Rothe P. Carl H. Swoboda B. (2004) Tenascin and aggrecan expression by articular chondrocytes is influenced by interleukin 1beta: a possible explanation for the changes in matrix synthesis during osteoarthritis. Ann Rheum Dis 63: 240–244.
99. Qatanani M. Szwergold N. Greaves D. Ahima R. Lazar M. (2009) Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest 119: 531–539.
100. Raynauld J. Martel-Pelletier J. Bias P. Laufer S. Haraoui B. Choquette D. et al. (2009) Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis 68: 938–947.
101. Roemer F. Guermazi A. Felson D. Niu J. Nevitt M. Crema M. et al. (2011) Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 30-month follow-up: the MOST study. Ann Rheum Dis 70: 1804–1809.
102. Rosenthal A. (2011) Crystals, inflammation, and osteoarthritis. Curr Opin Rheumatol 23: 170–173.
103. Saklatvala J. (1986) Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322: 547–549.
104. Scanzello C. Goldring S. (2012) The role of synovitis in osteoarthritis pathogenesis. Bone 51: 249–257.
105. Scanzello C. McKeon B. Swaim B. DiCarlo E. Asomugha E. Kanda V. et al. (2011) Synovial inflammation in patients undergoing arthroscopic meniscectomy: molecular characterization and relationship to symptoms. Arthritis Rheum 63: 391–400.
106. Scanzello C. Plaas A. Crow M. (2008) Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound? Curr Opin Rheumatol 20: 565–572.
107. Scanzello C. Umoh E. Pessler F. Diaz-Torne C. Miles T. Dicarlo E. et al. (2009) Local cytokine profiles in knee osteoarthritis: elevated synovial fluid interleukin-15 differentiates early from end-stage disease. Osteoarthritis Cartilage 17: 1040–1048.
108. Schaefer L. Babelova A. Kiss E. Hausser H. Baliova M. Krzyzankova M. et al. (2005) The matrix component biglycan is proinflammatory and signals through toll-like receptors 4 and 2 in macrophages. J Clin Invest 115: 2223–2233.
109. Schelbergen R. Blom A. van den Bosch M. Sloetjes A. Abdollahi-Roodsaz S. Schreurs B. et al. (2012) Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on toll-like receptor 4. Arthritis Rheum 64: 1477–1487.
110. Sellam J. Berenbaum F. (2010) The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol 6: 625–635.
111. Singh J. Furst D. Bharat A. Curtis J. Kavanaugh A. Kremer J. et al. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64: 625–639.
112. Sjoberg A. Manderson G. Morgelin M. Day A. Heinegard D. Blom A. (2009) Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol Immunol 46: 830–839.
113. Skrzeczynska-Moncznik J. Stefanska A. Zabel B. Kapinska-Mrowiecka M. Butcher E. Cichy J. (2009) Chemerin and the recruitment of NK cells to diseased skin. Acta Biochim Pol 56: 355–360.
114. Smiley S. King J. Hancock W. (2001) Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 167: 2887–2894.
115. Smith M. Triantafillou S. Parker A. Youssef P. Coleman M. (1997) Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 24: 365–371.
116. Sohn D. Sokolove J. Sharpe O. Erhart J. Chandra P. Lahey L. et al. (2012) Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via toll-like receptor 4. Arthritis Res Ther 14: R7.
117. Song I. Althoff C. Hermann K. Scheel A. Knetsch T. Schoenharting M. et al. (2008) Knee osteoarthritis. Efficacy of a new method of contrast-enhanced musculoskeletal ultrasonography in detection of synovitis in patients with knee osteoarthritis in comparison with magnetic resonance imaging. Ann Rheum Dis 67: 19–25.
118. Soren A. Klein W. Huth F. (1976) Microscopic comparison of the synovial changes in posttraumatic synovitis and osteoarthritis. Clin Orthop Relat Res (121): 191–195.
119. Spector T. Hart D. Nandra D. Doyle D. Mackillop N. Gallimore J. et al. (1997) Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 40: 723–727.
120. Stahel P. Smith W. Moore E. (2007) Role of biological modifiers regulating the immune response after trauma. Injury 38: 1409–1422.
121. Steenvoorden M. Bank R. Ronday H. Toes R. Huizinga T. DeGroot J. (2007) Fibroblast-like synoviocyte-chondrocyte interaction in cartilage degradation. Clin Exp Rheumatol 25: 239–245.
122. Su S. Tsai C. Lee C. Salter D. Lee H. (2005) Expression and regulation of toll-like receptor 2 by IL-1beta and fibronectin fragments in human articular chondrocytes. Osteoarthritis Cartilage 13: 879–886.
123. Telander D. (2011) Inflammation and age-related macular degeneration (AMD). Semin Ophthalmol 26: 192–197.
124. Termeer C. Benedix F. Sleeman J. Fieber C. Voith U. Ahrens T. et al. (2002) Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 195: 99–111.
125. Ushiyama T. Chano T. Inoue K. Matsusue Y. (2003) Cytokine production in the infrapatellar fat pad: another source of cytokines in knee synovial fluids. Ann Rheum Dis 62: 108–112.
126. van de Loo F. Kuiper S. van Enckevort F. Arntz O. van den Berg W. (1997) Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice. Am J Pathol 151: 177–191.
127. Vangsness C. Jr Burke W. Narvy S. MacPhee R. Fedenko A. (2011) Human knee synovial fluid cytokines correlated with grade of knee osteoarthritis – a pilot study. Bull NYU Hosp Jt Dis 69: 122–127.
128. van Lent P. Blom A. Schelbergen R. Sloetjes A. Lafeber F. Lems W. et al. (2012) Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. Arthritis Rheum 64: 1466–1476.
129. Wang Q. Rozelle A. Lepus C. Scanzello C. Song J. Larsen D. et al. (2011) Identification of a central role for complement in osteoarthritis. Nat Med 17: 1674–1679.
130. Wittenberg R. Willburger R. Kleemeyer K. Peskar B. (1993) In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. Arthritis Rheum 36: 1444–1450.
131. Wyss-Coray T. (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12: 1005–1015.